Skip to Content

Canopy Growth Corp CGC

Morningstar Rating
$0.69 +0.03 (4.22%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

Company Report

Canopy Continues to Face Risks From Cash Burn and Equity Dilution Even as Losses Narrow

Canopy Growth grows and sells cannabis products primarily in Canada, which accounts for roughly 60% of sales. Unfortunately, the Canadian market is overloaded with too many licensed producers, leading to tough price competition and a stubbornly robust illicit market, so Canopy has yet to reach profitability. We forecast mid-single-digit growth over the next decade for the Canadian market, driven by the conversion of illicit consumers into the legal market. We expect competition to ease as continued industry losses drive consolidation.

Price vs Fair Value

CGC is trading at a 22% discount.
Price
$0.67
Fair Value
$5.26
Uncertainty
Extreme
1-Star Price
$4.60
5-Star Price
$9.99
Economic Moat
Pqkm
Capital Allocation
Srx

Bulls Say, Bears Say

Bulls

Canopy Growth’s plans to create Canopy USA to strengthen its competitive position before U.S. federal legalization.

Bears

While Canopy waits for U.S. federal legalization to enter the THC market there, U.S. multistate operators continue to grow bigger and become more competitive.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CGC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.66
Day Range
$0.670.73
52-Week Range
$0.354.27
Bid/Ask
$0.69 / $0.70
Market Cap
$573.56 Mil
Volume/Avg
24.2 Mil / 50.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.58
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include sports drink BioSteel, skincare products under This Works, Martha Stewart CBD, and Storz & Bickel vaporizers. Canopy growth is attempting to merge its U.S. assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
1,621

Competitors

Valuation

Metric
CGC
CURLF
ACB
Price/Earnings (Normalized)
Price/Book Value
1.002.630.54
Price/Sales
1.582.110.85
Price/Cash Flow
Price/Earnings
CGC
CURLF
ACB

Financial Strength

Metric
CGC
CURLF
ACB
Quick Ratio
1.730.291.43
Current Ratio
2.520.873.29
Interest Coverage
−8.17−2.47
Quick Ratio
CGC
CURLF
ACB

Profitability

Metric
CGC
CURLF
ACB
Return on Assets (Normalized)
−1.72%−6.81%
Return on Equity (Normalized)
−4.05%−17.81%
Return on Invested Capital (Normalized)
2.49%−6.76%
Return on Assets
CGC
CURLF
ACB

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class APzrlq$82.5 Bil
MKKGY
Merck KGaA ADRXzcmdn$77.2 Bil
HLN
Haleon PLC ADRWhhrp$37.9 Bil
RDY
Dr Reddy's Laboratories Ltd ADRQzlr$11.5 Bil
VTRS
Viatris IncYds$11.5 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRNfht$11.4 Bil
CTLT
Catalent IncTkdghsn$7.0 Bil
PRGO
Perrigo Co PLCKwx$4.2 Bil
PBH
Prestige Consumer Healthcare IncZhwbqj$3.0 Bil
CURLF
Curaleaf Holdings IncFkxfz$2.9 Bil